Prescription patterns of sacubitril/valsartan among patients with hypertension in Japan - Takeaways - MDSpire

Analysis of Sacubitril/Valsartan Prescribing Trends in Hypertensive Patients in Japan

  • By

  • Aya F. Ozaki

  • Hisanaga Nomura

  • Tomohiro Terada

  • Eri T. Kato

  • Ali A. Naqvi

  • Julie T. Nguyen

  • Yuki Kunitsu

  • July 17, 2026

Share

  • 1

    Sacubitril/valsartan (S/V) is approved for hypertension in Japan, although primarily used for heart failure in Western countries.

  • 2

    A total of 9,486 patients with hypertension were initiated on S/V, with a median age of 79 years and 50.6% being men.

  • 3

    63.6% of patients received S/V in combination with a calcium channel blocker (CCB), while 22.5% received it as monotherapy.

  • 4

    By day 90, 11.8% of patients discontinued S/V, with 55.5% remaining on S/V plus a CCB and 26.0% on S/V monotherapy.

  • 5

    Approximately half of patients on triple therapy with S/V, CCB, and thiazide discontinued the thiazide within 30 days.

Original Source(s)

Prescription patterns of sacubitril/valsartan among patients with hypertension in Japan

  • by Aya F. Ozaki, Hisanaga Nomura, Tomohiro Terada, Eri T. Kato, Ali A. Naqvi, Julie T. Nguyen, Yuki Kunitsu

  • July 17, 2026

Related Content

Reliability and device objectivity in oscillatory blood pressure measurement – a measurement error analysis to inform clinical decision making

Pre–existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18–30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data

Explainable machine learning for hypertension prevalence classification: a cross-sectional study in Hainan Province, China